Fulcrum Therapeutics, Inc. (FULC)

Market Cap	437.26M
Revenue (ttm)	2.81M
Net Income (ttm)	-97.34M
Shares Out	61.94M
EPS (ttm)	-1.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	511,377
Open	7.15
Previous Close	7.15
Day's Range	6.90 - 7.21
52-Week Range	2.43 - 13.70
Beta	2.28
Analysts	Buy
Price Target	13.17 (+86.54%)
Earnings Date	May 13, 2024

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discove...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: FULC

Financial Performance

In 2023, FULC's revenue was $2.81 million, a decrease of -55.77% compared to the previous year's $6.34 million. Losses were -$97.34 million, -11.41% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is $13.17, which is an increase of 86.54% from the latest price.

Price Target

$13.17

(86.54% upside)

Analyst Consensus: Buy